{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/63f4e3bd1561a700115e8a47?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What do HCPs need to know about LN and the prevention of progression to ESRD? ","description":"<p>The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to end-stage renal disease (ESRD)?</p><p><br></p><p>Urowitz begins by highlighting the incidence of ESRD in patients with lupus, with estimates ranging from 8% to 17% over 10 years. He then examines the factors associated with advancement to Grade 4 and 5 chronic kidney disease. He also presents data on the relationship between time to remission, number of flares in the first 5 years after initial remission, and the number of years a patient is on immunosuppressant therapy with the development of chronic kidney disease. Finally, he discusses how this data could inform lupus treatment and ultimately reduce the incidence of progression to ESRD.</p>","author_name":"Scientific Education Support"}